Quantcast
Last updated on April 19, 2014 at 17:21 EDT

Latest NFE2L2 Stories

2013-10-23 10:19:04

New research by scientists at UC San Francisco shows that one of the brain's fundamental self-protection mechanisms depends on coordinated, finely calibrated teamwork among neurons and non-neural cells knows as glial cells, which until fairly recently were thought to be mere support cells for neurons. The study, which has implications for understanding neurodegenerative diseases, stroke, and other nervous system disorders, adds to a growing body of evidence that glial cells are integral to...

2013-10-14 09:24:31

University of Utah researchers have found that deficiency of an antioxidant response protein called nuclear erythroid-2 like factor-2 (Nrf2) delays or prevents hypertrophic cardiomyopathy, a type of a heart failure in which the heart muscle grows abnormally thick. This new finding, published in the Oct. 1, 2013, issue of Cardiovascular Research, suggests that restoring the normal balance of reduction-oxidation chemical reactions in the body could prevent heart disease and other conditions...

2013-09-12 13:30:43

Japanese researchers have identified a mutation associated with a higher incidence of lung cancer in Japanese women who do not smoke, but better survival in lung cancer patients. In a study published today in the journal PLOS ONE, the team from the RIKEN Center for Life Science Technologies shows that a single nucleotide polymorphism (SNP) in a gene that protects cells from oxidative stress is found four times more frequently in women than in men. Lung cancer is the leading cause of...

2013-03-20 23:00:30

Chronic inflammation contributes to a host of medical conditions affecting people, companion pets and horses but being proactive can help keep that inflammation under control. Cur-OST® is a curcumin based all natural anti-inflammatory supplement that has demonstrated the ability to reduce chronic inflammation through modulation of two key transcription factors; NF-kB and NRF2, thereby reducing inflammation and also enhancing the immune response which may impact a variety of clinical...

2012-07-23 20:48:38

A new and powerful class of antioxidants could one day be a potent treatment for Parkinson's disease, researchers report. A class of antioxidants called synthetic triterpenoids blocked development of Parkinson's in an animal model that develops the disease in a handful of days, said Dr. Bobby Thomas, neuroscientist at the Medical College of Georgia at Georgia Health Sciences University and corresponding author of the study in the journal Antioxidants & Redox Signaling. Thomas and...

2012-02-06 09:00:00

A newly published study, investigating the proper blood vessel formation (angiogenesis), implicates a specific factor (Nrf2) in premature aging of the blood vessels, as well as their improper healing. Expanding on this study Nutri-Med Logic Corp says that Nrf2, also known as a physiological regulator of oxidative stress, plays an important part in general premature aging as well as many diseases, ranging from Arthritis to Alzheimer. Miami, Florida (PRWEB) February 06, 2012 A new study,...

2012-01-06 08:00:00

IRVING, Texas, Jan. 6, 2012 /PRNewswire/ -- Reata Pharmaceuticals, Inc. today announced that Warren Huff, President and CEO, will present a company overview at the 30th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 10, at 10:00 a.m. PST in the Elizabethan C/D Room at the Westin St. Francis Hotel in San Francisco, CA. Mr. Huff's presentation will include an update on the development of bardoxolone methyl, a first-in-class antioxidant...

2011-12-12 05:00:00

ABBOTT PARK, Ill. and IRVING, Texas, Dec. 12, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) and Reata Pharmaceuticals today announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators (AIMs). The agreement is in addition to the partnership between the two companies announced in September 2010 in which Reata granted to Abbott exclusive rights to develop and...

2011-11-29 07:00:00

IRVING, Texas, Nov. 29, 2011 /PRNewswire/ -- A new study in The Journal of Clinical Investigation (JCI) has uncovered a novel mechanism that cancer cells may use to escape detection by the body's immune system. The study, "Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice," led by researchers at the H. Lee Moffitt Cancer Center in Tampa, Fla., shows that a specific type of immature white blood cells (myeloid derived suppressor cells or...

2011-06-24 09:15:00

IRVING, Texas and ABBOTT PARK, Ill., June 24, 2011 /PRNewswire/ -- New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate (eGFR). The data were also presented today in a Late-Breaking...